NYSE:JNJ   Johnson & Johnson
jnj 170 target, vaccine one dose approval imminent . money flow increasing
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.